We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Santarus, Inc. (MM) | NASDAQ:SNTS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 31.97 | 0 | 01:00:00 |
Salix Pharmaceuticals, Ltd.
8510 Colonnade Center Drive
Raleigh, North Carolina 27615
April 1, 2015
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3628
RE: | Salix Pharmaceuticals, Ltd. |
Registration Statement on Form S-4 (File No. 333-196425)
Ladies and Gentlemen:
Pursuant to Rule 477 under the Securities Act of 1933 (the Securities Act), Salix Pharmaceuticals, Ltd. (the Company) hereby respectfully requests the withdrawal of the Companys Registration Statement on Form S-4 (File no. 333-196425) filed with the Securities and Exchange Commission (the Commission) on May 30, 2014, together with all exhibits thereto (the Registration Statement). The Registration Statement was never declared effective and no securities have been sold or exchanged pursuant thereto. Because the proposed offering of the securities under the Registration Statement will not occur, the Company believes that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by Rule 477(a) under the Securities Act.
The Company acknowledges that no refund will be made for fees paid to the Commission. However, in accordance with Rule 457(p) under the Securities Act, the Company hereby requests that the total fees paid to the Commission in the amount of $96,600 be offset against the total filing fee due for subsequent Commission filings.
Should you have any questions on this matter, please contact Alison S. Ressler or Sarah P. Payne of Sullivan & Cromwell LLP at (310) 712-6630 and (650) 461-5669, respectively.
Sincerely, | ||
Salix Pharmaceuticals, Ltd. | ||
By: | /s/ Robert R. Chai-Onn | |
Name: | Robert R. Chai-Onn | |
Title: | Executive Vice President, General Counsel and Secretary |
cc: | Alison S. Ressler |
Sarah P. Payne
(Sullivan & Cromwell LLP)
1 Year Santarus Chart |
1 Month Santarus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions